Remove 2009 Remove Manufacturing Remove Pharmaceutical
article thumbnail

Beverage manufacturer names Enrico De La Torre as new Commercial Director of Canadian office

Canadian Manufacturing

CERRITOS — Electrolit – a hydration beverage made from pharmaceutical grade ingredients – announces that Enrico De La Torre is the company’s new Commercial Director for the Canada office. Enrico De La Torre.

article thumbnail

Cleantech Oxyle Powers Wastewater Treatment with Funding

MEM

All over the world precious bodies of water are contaminated with micropollutants such as pesticides, pharmaceuticals, and PFAS chemicals. was drastically lowered from 400 ppt (ng/L) in 2009 to 0.004 ppq (pg/L), a 100,000x stricter level due to the danger these chemicals pose to humans when consumed. from contaminated wastewater.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

METRO announces that Jean-Michel Coutu will be appointed new president of The Jean Coutu Group (PJC) Inc.

Canadian Manufacturing

Mr. Coutu has been with the company since 2009 after working in the industry for several years. Champagne has been involved in the combination of the Jean Coutu Group and METRO. METRO reports that though he leaves the pharmacy division, the banners and the pharmacists are well positioned for the future.

article thumbnail

Top Legal Issues Facing the Manufacturing Sector in 2023

Foley

Agility and resiliency remain essential attributes for manufacturers in 2023. Manufacturers are no longer focused on figuring out when things will return to “normal.” Most major automobile manufacturers have set aggressive goals to electrify their fleets, many in the range of 40-50% by the mid-2030s.

article thumbnail

Building an Integrated, End-to-End R&D and Manufacturing Service Platform with Innovative R&D and High-end Preparation Technologies

Frost & Sullivan Manufacturing

Aligning with Industry Trends: Healthnice Advances Step by Step Amid the global pharmaceutical industry’s evolution, high-end preparations have become a mainstream trend in drug development. Therefore, for pharmaceutical companies, high-end preparations represent a high-value, cost-effective strategy for differentiation.

article thumbnail

Transformational Growth Leadership: An Exclusive Interview with Yvonne Lungershausen, CEO, Avance Clinical

Frost & Sullivan Manufacturing

In 2009, Yvonne Lungershausen became a Founding Member of CPR Pharma Services (CPR) as it spun out from the University of South Australia. His in-depth understanding of the precision health ecosystem enables him to guide companies in identifying growth opportunities across contract research, development, and manufacturing services.